– USA, MA – Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a $115 million Series B financing with a premier syndicate of life science investors led by TCG Crossover alongside new investors including RA Capital Management, Surveyor Capital, Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital. Existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb participated in the financing. Also participating in the round is Vertex Pharmaceuticals, with whom Obsidian recently executed a collaboration to discover novel therapies that regulate gene editing.
Concurrent with the financing, Cariad Chester, Partner, TCGX, will join the Board of Directors.
“Obsidian’s cytoTIL15 therapy has the potential to be paradigm-shifting for patients with solid tumors. By engineering TILs with membrane-bound IL15, cytoTIL15 have the potential to drive improved efficacy as well as eliminate the need for toxic and costly concomitant IL2 therapy,” said Cariad Chester. “We are thrilled to support the Obsidian team as they pave the way for cytoTIL15 and the next generation of ‘TIL 2.0’ therapies.”
Proceeds from the financing will be used to drive Obsidian’s lead tumor-infiltrating lymphocyte program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the Company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.
“We are pleased to have the support and partnership from this syndicate of premier investors,” said CEO, Paul Wotton. “With this funding, we will continue to advance our transformative cytoTIL15 program into clinical studies to treat patients suffering from solid tumors and to further expand our pipeline of engineered TIL therapies.”
About Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals.
For more information: https://obsidiantx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.